Late Acquired Malaposition and Different Polymers

Phase 4CompletedNCT02018991

Medical University of Vienna69 enrolled

Overview

The polymers releasing the drug of first-generation drug-eluting stents (DES) may induce allergic reactions and inflammation, resulting in late-acquired stent malaposition (LASM) with uncoverage of struts, and risk of stent thrombosis. The incidence and predictors of LASM in DES with newer-generation polymers designed to improve biocompatibility are unknown.

please see brief summary

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Late Acquired Stent Malaposition

Interventions

Everolimus-Eluting Stent (EES)PROCEDURE

Patients treated with EES

Zotarolimus-Eluting-Stent (ZES)PROCEDURE

Patients treated with ZES

Biolimus-Eluting-Stent (BES)PROCEDURE

Patients treated with BES

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who underwent an elective treatment of a coronary lesion \> 20mm with a DES Exclusion Criteria: * chronic renal failure (serum creatinine ≥ 2.5mg/dl) * restenotic lesions

Locations (1)

Medical University of Vienna

Vienna, Austria

Outcomes

Primary Outcomes

Number of stent struts with late acquired malaposition

Time frame: 1 year after stent implantation

Secondary Outcomes

number of stent struts with late acquired malaposition

Time frame: 2 years after stent implantation

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.